Alnylam Pharma (ALNY) Posts Q3 adj.-Loss of $0.23, Beats by 1c
ALNY Hot Sheet
EPS Growth %: +10.7%Financial Fact:
Total other income (expense): -475K
Today's EPS Names:
VSNT, CIM, KH, More
Alnylam Pharmaceuticals (NASDAQ: ALNY) reports Q3 adjusted loss of $0.23, 1 cent better than the analyst estimate of ($0.24). Revenue for the quarter was $24.20 million, which compares to the estimate of $26.29 million.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- NetApp (NTAP) Slammed On Weak Outlook
- AFC Enterprises, Inc. (AFCE) Tops Q1 EPS by 4c; Raises FY12 Comps Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
